News of Note—Gritstone Oncology, Inovio Pharmaceuticals and more

In this week's News of Note, Gritstone Oncology hired a CFO from Actelion. (Pixabay)

Here is some other vaccine news of note for the week:

> Gritstone Oncology lured Actelion CFO Jean-Marc Bellemin for the same role. Release

> A universal flu vaccine candidate from Inovio Pharmaceuticals elicited immune responses against H1N1 strains from the past 100 years in animal models. Release

> Immunovaccine tapped Merck & Co. executive Joseph Sullivan as a senior vice president of business development. Release

> The Wistar Institute won a $1.4 million grant from the Gates Foundation to work on a second-generation malaria vaccine. Release

> Florida lawmakers are weighing a bill that would make HPV vaccination a requirement for public school students. ABC Action News story

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.